Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.8565
0.001600.19%
At close: -
Comments
Loading...
Kairos Pharma Analyst Ratings and Price Targets | AMEX:KAPA | Benzinga
Kairos Pharma Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Kairos Pharma Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
D. Boral Capital
HC Wainwright & Co.
Maxim Group
EF Hutton
1calculated from analyst ratings
Analyst Ratings for Kairos Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/17/2025 | Buy Now | — | D. Boral Capital | Jason Kolbert44% | $9 → $9 | Maintains | Buy | Get Alert |
| 04/03/2025 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis46% | → $12 | Initiates | → Buy | Get Alert |
| 03/31/2025 | Buy Now | — | D. Boral Capital | Jason Kolbert44% | $9 → $9 | Maintains | Buy | Get Alert |
| 03/27/2025 | Buy Now | — | Maxim Group | Jason McCarthy42% | → $4 | Initiates | → Buy | Get Alert |
| 03/20/2025 | Buy Now | — | D. Boral Capital | Jason Kolbert44% | $9 → $9 | Maintains | Buy | Get Alert |
| 02/26/2025 | Buy Now | — | D. Boral Capital | Jason Kolbert44% | $9 → $9 | Maintains | Buy | Get Alert |
| 02/18/2025 | Buy Now | — | D. Boral Capital | Jason Kolbert44% | $9 → $9 | Maintains | Buy | Get Alert |
| 02/12/2025 | Buy Now | — | D. Boral Capital | Jason Kolbert44% | $9 → $9 | Maintains | Buy | Get Alert |
| 01/22/2025 | Buy Now | — | D. Boral Capital | Jason Kolbert44% | $9 → $9 | Maintains | Buy | Get Alert |
| 11/14/2024 | Buy Now | — | D. Boral Capital | Jason Kolbert44% | $9 → $9 | Maintains | Buy | Get Alert |
| 10/14/2024 | Buy Now | — | EF Hutton | Jason Kolbert44% | → $9 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Kairos Pharma (KAPA) stock?
The latest price target for Kairos Pharma (AMEX:KAPA) was reported by D. Boral Capital on April 17, 2025. The analyst firm set a price target for $9.00 expecting KAPA to fall to within 12 months (a possible NaN% downside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Kairos Pharma (KAPA)?
The latest analyst rating for Kairos Pharma (AMEX:KAPA) was provided by D. Boral Capital, and Kairos Pharma maintained their buy rating.
When was the last upgrade for Kairos Pharma (KAPA)?
There is no last upgrade for Kairos Pharma
When was the last downgrade for Kairos Pharma (KAPA)?
There is no last downgrade for Kairos Pharma.
When is the next analyst rating going to be posted or updated for Kairos Pharma (KAPA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kairos Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kairos Pharma was filed on April 17, 2025 so you should expect the next rating to be made available sometime around April 17, 2026.
Is the Analyst Rating Kairos Pharma (KAPA) correct?
While ratings are subjective and will change, the latest Kairos Pharma (KAPA) rating was a maintained with a price target of $9.00 to $9.00. The current price Kairos Pharma (KAPA) is trading at is $undefined, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
